Equities research analysts expect Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) to post earnings of ($2.13) per share for the current quarter, Zacks Investment Research reports. Ten analysts have provided estimates for Ultragenyx Pharmaceutical’s earnings, with the highest EPS estimate coming in at ($1.92) and the lowest estimate coming in at ($2.36). Ultragenyx Pharmaceutical reported earnings per share of ($1.72) in the same quarter last year, which suggests a negative year over year growth rate of 23.8%. The company is scheduled to report its next earnings results on Thursday, July 26th.
According to Zacks, analysts expect that Ultragenyx Pharmaceutical will report full-year earnings of ($5.32) per share for the current fiscal year, with EPS estimates ranging from ($7.31) to ($3.80). For the next year, analysts anticipate that the company will report earnings of ($6.88) per share, with EPS estimates ranging from ($8.71) to ($4.32). Zacks’ EPS averages are an average based on a survey of research analysts that follow Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Monday, May 7th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.81. The business had revenue of $10.68 million during the quarter, compared to analysts’ expectations of $56.58 million. During the same period in the prior year, the business posted ($1.63) EPS.
RARE has been the subject of a number of recent analyst reports. Bank of America raised their price target on shares of Ultragenyx Pharmaceutical from $61.00 to $72.00 in a report on Tuesday, April 17th. Stifel Nicolaus reaffirmed a “buy” rating and set a $74.00 price target (down from $85.00) on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 21st. Robert W. Baird reaffirmed a “buy” rating and set a $70.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, February 23rd. BidaskClub raised shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, April 14th. Finally, SunTrust Banks raised shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating and raised their price target for the company from $41.67 to $55.00 in a report on Wednesday, April 18th. One analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. Ultragenyx Pharmaceutical presently has an average rating of “Buy” and an average price target of $70.06.
Shares of Ultragenyx Pharmaceutical traded up $2.67, reaching $80.25, during mid-day trading on Friday, MarketBeat Ratings reports. The company’s stock had a trading volume of 30,141 shares, compared to its average volume of 555,610. The company has a market cap of $3.64 billion, a PE ratio of -10.70 and a beta of 1.97. Ultragenyx Pharmaceutical has a 12-month low of $41.67 and a 12-month high of $77.62.
In other Ultragenyx Pharmaceutical news, CFO Shalini Sharp sold 13,000 shares of the firm’s stock in a transaction on Wednesday, May 30th. The shares were sold at an average price of $70.17, for a total transaction of $912,210.00. Following the completion of the transaction, the chief financial officer now directly owns 70,174 shares of the company’s stock, valued at approximately $4,924,109.58. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Matthew K. Fust sold 6,319 shares of the firm’s stock in a transaction on Wednesday, May 30th. The stock was sold at an average price of $72.00, for a total transaction of $454,968.00. Following the transaction, the director now directly owns 8,750 shares of the company’s stock, valued at $630,000. The disclosure for this sale can be found here. Over the last three months, insiders have sold 20,784 shares of company stock valued at $1,455,078. 8.40% of the stock is owned by company insiders.
Hedge funds have recently made changes to their positions in the business. Candriam Luxembourg S.C.A. grew its holdings in Ultragenyx Pharmaceutical by 23.3% during the 4th quarter. Candriam Luxembourg S.C.A. now owns 74,000 shares of the biopharmaceutical company’s stock worth $3,432,000 after acquiring an additional 14,000 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. grew its holdings in Ultragenyx Pharmaceutical by 1,246.9% during the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,273 shares of the biopharmaceutical company’s stock worth $152,000 after acquiring an additional 3,030 shares in the last quarter. Kornitzer Capital Management Inc. KS acquired a new position in Ultragenyx Pharmaceutical during the 1st quarter worth $3,687,000. Paloma Partners Management Co acquired a new position in Ultragenyx Pharmaceutical during the 4th quarter worth $580,000. Finally, Swiss National Bank grew its holdings in Ultragenyx Pharmaceutical by 4.0% during the 4th quarter. Swiss National Bank now owns 69,952 shares of the biopharmaceutical company’s stock worth $3,244,000 after acquiring an additional 2,700 shares in the last quarter. 96.11% of the stock is owned by institutional investors.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.